Compare Global X Copper Miners ETF (COPX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Pfizer Inc — how do they compare? Global X Copper Miners ETF trades at $83.59 (market cap $7.37B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 21.7× Global X Copper Miners ETF's market cap, and Pfizer Inc pays a 6.14% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Pfizer Inc for 158 Days on average.
| COPX | PFE | |
|---|---|---|
Market Cap | $7.37B | $159.59B |
Volume | 1,988,532 | 30,937,010 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $29.02 |
52-Week Low | $57.43 | $23.67 |
Typical Hold Time | 50 Days | 158 Days |
Enterprise Value | — | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) is trading at $83.58, down 3.13% with a bearish technical signal. The ETF faces selling pressure with 15 sell signals versus 2 buy signals across technical indicators. Copper fundamentals remain strong with prices near all-time highs above $6.85 per pound, driven by AI infrastructure demand and supply constraints. Recent news highlights copper's critical role in electrification and AI infrastructure, though technical indicators suggest near-term weakness.
The long-term copper thesis remains compelling due to structural supply deficits and AI-driven demand growth. However, near-term risks include potential Federal Reserve policy impacts and mining equity underperformance relative to copper prices. The ETF offers operational leverage to copper prices but faces volatility from global surplus projections and macroeconomic factors.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
